Please assess the completion status of the following clinical trial:

Trial Title: HiFIT Study : Hip Fracture: Iron and Tranexamic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years,~* Osteoporotic Fractures of the upper end of the femur requiring surgical repair.~* Preoperative hemoglobin between 9.5 and 13 g/dl.~* Patient or relative signed informed consent or inclusion thanks to urgent inclusion procedure~Exclusion Criteria:~* Bone marrow disease or ongoing treatment (such as chemotherapy), which could interfere with bone marrow erythropoiesis,~* Known allergy or counter-indication to iron and/or to tranexamic acid,~* Uncontrolled arterial hypertension,~* Recent iron infusion (within one week),~* Blood transfusion within one week before inclusion or preoperative blood transfusion already scheduled,~* Any patient who cannot be transfused or has refused consent for a blood transfusion,~* Bedridden or very dependent patient (equivalent to GIR 1 or 2 class).~* Non-affiliation to French health care coverage,~* Adult patient protected under the law (guardianship),~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TXA + IIM (Type: EXPERIMENTAL): The patients randomized to this arm will have iron isomaltoside 1000 and tranexamic acid
- Placebo TXA + IIM (Type: EXPERIMENTAL): The patients randomized to this arm will have iron isomaltoside 1000 and Placebos tranexamic acid
- TXA + Placebo IIM (Type: EXPERIMENTAL): The patients randomized to this arm will have Placebos iron isomaltoside 1000 and tranexamic acid
- Placebo TXA + Placebo IIM (Type: EXPERIMENTAL): The patients randomized to this arm will have Placebos iron isomaltoside 1000 and Placebos tranexamic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).